Public Profile

Indivior, Inc.

Indivior, Inc., a leading global pharmaceutical company headquartered in the United States, is dedicated to transforming the treatment of addiction and related disorders. Founded in 2014, Indivior has established itself as a key player in the addiction treatment industry, focusing on innovative therapies that address opioid dependence and other substance use disorders. With a strong presence in North America and Europe, Indivior's core products, including SUBOXONE® and SUBLOCADE®, are designed to provide effective, long-term solutions for patients. These unique formulations not only enhance patient adherence but also contribute to reducing the stigma associated with addiction treatment. Recognised for its commitment to patient care and public health, Indivior continues to make significant strides in the market, positioning itself as a trusted partner in the fight against addiction.

DitchCarbon Score

How does Indivior, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

27

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

30

Industry Benchmark

Indivior, Inc.'s score of 27 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.

0%

Let us know if this data was useful to you

Indivior, Inc.'s reported carbon emissions

Indivior, Inc., headquartered in the US, currently does not have publicly available carbon emissions data or specific reduction targets. As such, there are no reported figures for their Scope 1, 2, or 3 emissions. The absence of emissions data suggests that the company may still be in the process of establishing its climate commitments or reporting frameworks. In the context of the pharmaceutical industry, many companies are increasingly focusing on sustainability and carbon reduction initiatives. Indivior's lack of disclosed targets may indicate an opportunity for future commitments to align with industry standards and expectations regarding climate action.

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Indivior, Inc.'s primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Indivior, Inc. is in US, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Indivior, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Aquestive Therapeutics, Inc.

US
Pharmaceutical Preparation Manufacturing
Updated 3 days ago

Orexo Us, Inc.

US
Pharmaceutical Preparation Manufacturing
Updated 3 days ago

BioDelivery Sciences International, Inc.

US
Pharmaceutical Preparation Manufacturing
Updated 3 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers